{"id":32,"date":"2009-10-23T15:09:37","date_gmt":"2009-10-23T19:09:37","guid":{"rendered":"https:\/\/www.bu.edu\/amyloid\/doctors\/trials\/"},"modified":"2022-11-03T12:42:47","modified_gmt":"2022-11-03T16:42:47","slug":"trials","status":"publish","type":"page","link":"https:\/\/www.bu.edu\/amyloid\/research\/trials\/","title":{"rendered":"Clinical Research"},"content":{"rendered":"\n\n\n\n\n
\n

Repository: All Types of Amyloidosis <\/strong><\/p>\n<\/td>\n<\/tr>\n

H-22838:<\/strong> Data, Tissue, Blood, And Urine Repository For Amyloid Diseases 2000-455G<\/td>\n<\/tr>\n
H-33317:<\/strong> Serum Biomarker Identification of Cardiac Amyloidosis in Elderly African Americans<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n\n\n\n\n
\n

AL Amyloidosis <\/strong><\/p>\n<\/td>\n<\/tr>\n

NCT05250973: A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (AQUARIUS)<\/td>\n<\/tr>\n
NCT04973137: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects With Light Chain (AL) Amyloidosis (AFFIRM-AL)<\/td>\n<\/tr>\n
NCT04512235: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Na\u00efve Patients With Mayo Stage IIIa AL Amyloidosis (CARES-302)<\/td>\n<\/tr>\n
NCT04504825: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Na\u00efve Patients With Mayo Stage IIIb AL Amyloidosis (CARES-301)<\/td>\n<\/tr>\n
NCT04270175: Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed\/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab<\/td>\n<\/tr>\n
NCT04847453: A Phase 1\/1a Study of Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for Relapsed\/Refractory Light Chain Amyloidosis<\/td>\n<\/tr>\n
NCT04316442: A Phase 1b\/2a, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Systemic AL Amyloidosis<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n
\n

ATTRwt (Wild Type) Amyloidosis<\/strong><\/p>\n<\/td>\n<\/tr>\n

H-28609:<\/strong> A Study of Serum Transthyretin Aggregates And Association With Disease Progression In Patients With Senile Systemic Amyloidosis<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n\n
\n

ATTRmt (Mutant TTR, Familial) Amyloidosis<\/strong><\/p>\n<\/td>\n<\/tr>\n

ISIS\u00a0420915-CS3<\/a><\/strong>:\u00a0\u00a0IONIS OPEN LABEL EXTENSION STUDY<\/strong>: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP)<\/td>\n<\/tr>\n
B3461045<\/a><\/strong>:\u00a0 TAFAMIDIS OPEN LABEL EXTENSION STUDY:<\/strong> A Multicenter, International, Phase 3, Double-Blind, Randomized, Extension Study to Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM)<\/td>\n<\/tr>\n
ALN-TTR02-006<\/a>: PATISIRAN OPEN LABEL EXTENSION STUDY<\/strong>: A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical Study<\/td>\n<\/tr>\n
ALN-TTR02-007<\/a>: PATISIRAN EXPANDED ACCESS PROGRAM<\/strong>: Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polyneuropathy<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Repository: All Types of Amyloidosis H-22838: Data, Tissue, Blood, And Urine Repository For Amyloid Diseases 2000-455G H-33317: Serum Biomarker Identification of Cardiac Amyloidosis in Elderly African Americans   AL Amyloidosis NCT05250973: A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (AQUARIUS) NCT04973137: A Phase 3, Randomized, Multicenter, Double-Blind, […]<\/p>\n","protected":false},"author":1952,"featured_media":0,"parent":1236,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.bu.edu\/amyloid\/wp-json\/wp\/v2\/pages\/32"}],"collection":[{"href":"https:\/\/www.bu.edu\/amyloid\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.bu.edu\/amyloid\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/amyloid\/wp-json\/wp\/v2\/users\/1952"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/amyloid\/wp-json\/wp\/v2\/comments?post=32"}],"version-history":[{"count":51,"href":"https:\/\/www.bu.edu\/amyloid\/wp-json\/wp\/v2\/pages\/32\/revisions"}],"predecessor-version":[{"id":4558,"href":"https:\/\/www.bu.edu\/amyloid\/wp-json\/wp\/v2\/pages\/32\/revisions\/4558"}],"up":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/amyloid\/wp-json\/wp\/v2\/pages\/1236"}],"wp:attachment":[{"href":"https:\/\/www.bu.edu\/amyloid\/wp-json\/wp\/v2\/media?parent=32"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}